ArticleInfectious diseases and therapy2025
Two Decades of Living with Echinococcus multilocularis: A Clinical Epidemiology Study on Human Alveolar Echinococcosis in Hungary.
Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Alveolar Echinococcosis in the Early 2020s: A Systematic Review.Pathogens (Basel, Switzerland) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
introductionThe zoonotic parasite Echinococcus multilocularis emerged in Hungary in the early 2000s. During the next two decades, it continuously spread in both wildlife and the human population. The first comprehensive epidemiological study on human alveolar echinococcosis (HAE) was carried out in 2018. Then, a remarkable increase in HAE cases was detected in Hungary.
methodsOur study aimed to identify the potential causes of trend alterations in the epidemiology of HAE. Thus, we compared the terms before (2003-2018) and after (2019-2024) the comprehensive analysis, focusing on disease outcomes and their associated background factors.
resultsWe found that, during the latter study period, the prognosis of HAE improved (proportion of improving cases increased from 23.5% to 60.9%, p = 0.0006) owing to the shortening of diagnostic delay (47.1% versus 78.3% of delay within 12 months, p = 0.029), development in surgery (17.6% versus 26.1% of surgeries were R1/R2, p = 0.57) and medication (35.3% versus 73.9% of medications proved adequate, p = 0.015); however, the proportion of advanced-stage cases entering the healthcare system remained high (56.25% versus 56.52%). On the other hand, a non-significant increase in case numbers was experienced in the southwestern part of the country (11.77% versus 26.09% of all cases in Hungary).
conclusionWe conclude that public interest arose from the first comprehensive HAE study that increased disease awareness within the healthcare system and contributed to better diagnoses and more efficient therapy. However, public awareness needs improvement, since the proportion of advanced-stage HAE did not decrease between the two study periods. Besides, the southwestern hotspot needs more attention and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.